Chordate Medical Holding AB’s (publ) shares are traded on Nasdaq First North Growth Market Stockholm as of today, February 15th

Chordate Medical announces that the Company’s shares are traded on the Nasdaq First North Growth Market (“First North”) as of today, February 15th, 2022. Chordate has received final approval from Nasdaq Stockholm AB and the Company’s shares are traded on First North as of today with unchanged short name CMH and ISIN code SE0009495559. The shareholders of Chordate do not need to take any action in connection with this.

Advisor
Västra Hamnen Corporate Finance AB is Chordate’s advisor regarding the list change and Certified Adviser. Wistrand Advokatbyrå AB is Chordate’s legal advisor.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical’s share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more at
 www.chordate.com

Chordate’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vastra Hamnen Corporate Finance AB, +46 40 200 250, ca@vhcorp.se.

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia®, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy